Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03318861 · ClinicalTrials.gov registry record · Phase 1
Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Terminated
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT03318861 is a Phase 1 study that was terminated before completion, run by Kite, A Gilead Company. The registered enrollment target is 17 participants.
The verdict
NCT03318861, a Phase 1 study, was terminated before completion, sponsored by Kite, A Gilead Company.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limiting toxicities (DLTs). Participants will be given a 3 day course of conditioning chemotherapy followed by a single infusion of KITE-585.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- GENETIC KITE-585
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2017-10-20 |
| Est. Completion | 2022-09-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03318861
The ClinicalTrials.gov registry entry for NCT03318861 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT03318861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03318861 about?
NCT03318861 is a clinical study titled "Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma". The primary objective of the study is to evaluate the safety and tolerability of KITE-585, an autologous engineered chimeric antigen receptor (CAR) T-cell product targeting a protein commonly found on myeloma cells called B-cell maturation antigen (BCMA), as measured by the incidence of dose-limitin...
What is the current status of trial NCT03318861?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2017-10-20. Estimated completion is 2022-09-16.
What interventions are being tested in trial NCT03318861?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-585 (GENETIC).
Who is sponsoring clinical trial NCT03318861?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.